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Other chronic ILDs with a progressive-fibrosing phenotype may have a clinical course similar to IPF.
Although challenging, identification of these patients is crucial, and requires a multidisciplinary
approach, to ensure optimal diagnosis and management. http://ow.ly/8q8M30mGDsQ
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the spectrum of progressive-fibrosing interstitial lung diseases. Eur Respir Rev 2018; 27: 180076 [https://doi.
org/10.1183/16000617.0076-2018].
ABSTRACT Although these conditions are rare, a proportion of patients with interstitial lung diseases
(ILDs) may develop a progressive-fibrosing phenotype. Progressive fibrosis is associated with worsening
respiratory symptoms, lung function decline, limited response to immunomodulatory therapies, decreased
quality of life and, potentially, early death. Idiopathic pulmonary fibrosis may be regarded as a model for
other progressive-fibrosing ILDs. Here we focus on other ILDs that may present a progressive-fibrosing
phenotype, namely idiopathic nonspecific interstitial pneumonia, unclassifiable idiopathic interstitial
pneumonia, connective tissue disease-associated ILDs (e.g. rheumatoid arthritis-related ILD), fibrotic
chronic hypersensitivity pneumonitis, fibrotic chronic sarcoidosis and ILDs related to other occupational
exposures. Differential diagnosis of these ILDs can be challenging, and requires detailed consideration of
clinical, radiological and histopathological features. Accurate and early diagnosis is crucial to ensure that
patients are treated optimally.
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Introduction
The term interstitial lung disease (ILD) encompasses a large group of > 200 parenchymal pulmonary
disorders, of which the majority are classified as rare [1, 2]. Early and accurate diagnosis can be
challenging, and it is difficult to predict disease progression. Most patients with ILDs are cared for by a
pulmonologist, but specialists from other disciplines may also be involved (e.g. rheumatologists) [3].
Idiopathic pulmonary fibrosis (IPF) and several other ILDs (such as hypersensitivity pneumonitis (HP),
rheumatoid arthritis-associated ILD (RA-ILD) and unclassifiable disease) may present a progressive-
fibrosing phenotype (figure 1).
IPF is the most widely studied and most common ILD. It is characterised by progressive fibrosis, lung
scarring and a radiological pattern known as usual interstitial pneumonia (UIP) [4–6]. There are a number
of clinical and mechanistic parallels between IPF and other fibrosing ILDs that may present a progressive
phenotype [7–9]. Given their overlapping clinical, radiological and pathological presentations, the
terminology recently used to describe patients with fibrosing ILDs that may present a progressive
phenotype, despite currently available treatment, is “progressive-fibrosing ILD (PF-ILD)” [1, 2, 9]. The
commonalities of ILDs that may present a progressive-fibrosing phenotype suggest the potential for a
common treatment pathway. Most patients will have a combination of inflammation and fibrosis, and the
effectiveness of immunomodulatory therapy varies between conditions (it is most likely to stabilise and/or
to slow disease progression in nonspecific interstitial pneumonia (NSIP), connective tissue
disease-associated ILD (CTD-ILD) and subsets of chronic fibrosis HP) [1].
Progressive fibrosis of the lung parenchyma is self-sustaining and causes progressive deterioration in lung
function, respiratory symptoms and quality of life [10, 11]. It therefore increases the risk of early death.
Pulmonary fibrosis is sometimes regarded as an indicator of disease progression, and the prognosis
associated with an ILD is generally worsened by its presence [1]. However, aside from IPF, ILDs with
progressive fibrosis may be clinically stable, especially if the disease is mild. In addition, a progressive
phenotype can exist in the absence of pulmonary fibrosis. One question in this regard is how the term
“progressive” should be defined. There are no uniformly accepted criteria, but we suggest patients meeting
any of the following criteria within a 24-month period have experienced disease progression: a relative
decline of ⩾10% in forced vital capacity (FVC); a relative decline of ⩾15% in diffusing capacity of the lung
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for carbon monoxide (DLCO); or worsening symptoms or a worsening radiological appearance
accompanied by a ⩾5–<10% relative decrease in FVC [1, 12].
In this review, we explore the current understanding of fibrosing ILDs (other than IPF) that may present a
progressive phenotype and consider how they are diagnosed, highlighting similarities and differences
between their presentation and clinical course. Fibrosis is a common characteristic in some patients with
interstitial pneumonia with autoimmune features (IPAF). However, IPAF is not an established diagnostic
entity: IPAF criteria were constructed by the European Respiratory Society (ERS)/American Thoracic Society
(ATS) Task Force in order to standardise research but have yet to be validated in clinical practice [13, 14].
Idiopathic pleuroparenchymal fibroelastosis has been excluded because this disease is not limited to the lung
parenchyma and there is no conclusive evidence to enable definitive consideration of its histology and
natural course. Several further ILDs with an intermediate frequency of progressive fibrosis have also been
excluded, such as inflammatory myopathy, mixed connective tissue disease (CTD) or desquamative
interstitial pneumonia. Although these diseases are considered outside the scope of this review, they may be
considered as possibilities during diagnostic workup.
Diagnostic methods
The differential diagnosis of ILDs requires a multidisciplinary approach, usually involving pulmonologists,
radiologists and pathologists [15]. Evaluations include clinical presentation, specific history assessment,
smoking status, lung function evolution, serological test results, imaging and, if required, lung biopsy [4, 5, 16].
In nearly all cases, high-resolution computed tomography (HRCT) is the primary tool for diagnosis [5].
HRCT (in particular, the fibrosis score) can also help determine the prognosis in ILDs, and quantitative
computed tomography (CT) analysis may be useful for evaluating disease progression [17–19] (the article
by WALSH et al. [20] in this issue of the European Respiratory Review provides more detail on imaging in
fibrosing ILDs that may present a progressive phenotype). ILD diagnoses should be categorised as
confident, provisional or unclassifiable depending on the level of diagnostic confidence. Based on current
knowledge, we would propose the (previously unpublished) algorithm shown in figure 2 for diagnosing
ILDs that may present a progressive-fibrosing phenotype; clinical data are needed to refine and validate
this approach.
M
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ILD
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FIGURE 2 Diagnosis of fibrosing interstitial lung diseases (ILD) that may present a progressive phenotype.
PFTs: pulmonary function test; HCRT: high-resolution computed tomography; BAL: bronchoalveolar lavage;
MDD: multidisciplinary diagnosis; PF-ILD: progressive-fibrosing ILD.
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With due consideration of the clinical context, serological testing can determine whether there is an
underlying autoimmune disease or autoreactive component [4]. Lung biopsy and bronchoscopy tend to be
reserved for the minority of cases where other assessments are inconclusive. The risk of complications
(including acute exacerbations of underlying disease) and mortality must be considered before a biopsy is
undertaken, although novel methods such as transbronchial cryobiopsy may reduce the risks.
Bronchoalveolar lavage is helpful for the diagnosis of some ILDs, although it may not be required in
typical IPF (or UIP) [4].
Lung function tests and blood gas analyses usually have limited diagnostic value, because restrictive lung
capacity and abnormal gas exchange are common to all ILDs with fibrosis [21]. However, they can help
determine the severity of disease and the prognosis, and occasionally refine a working diagnosis based on
disease behaviour [22–28]. Through serial measurements, lung function tests (particularly FVC) provide
the primary means of monitoring disease progression [21].
Presentation and clinical course of fibrosing ILDs that may present a progressive
phenotype, other than IPF
Idiopathic interstitial pneumonias
Idiopathic interstitial pneumonia (IIP) is a term used to describe a wide range of ILDs characterised by
unique clinical, radiological and pathological features [29]. IPF is the most common type of IIP,
accounting for ∼50% of all IIPs [30]. Diagnosis of patients with IIP can be challenging due to the mixed
patterns of lung injury that can be observed [16, 31]. Within this classification, there are at least two
entities that can develop a progressive-fibrosing phenotype and present similar clinical features to those
seen in IPF: idiopathic NSIP (iNSIP) and unclassifiable IIP.
iNSIP
iNSIP accounts for about one-quarter of all IIPs [30]. Although the aetiology of iNSIP is unknown, the
disease is more common in women, never-smokers and in individuals in their sixth decade of life [32, 33].
The diagnosis of iNSIP is predominantly a process of exclusion, where the possibility of a CTD or an ILD
with autoimmune features should be ruled out. On HRCT, iNSIP exhibits peripheral, basal, symmetric,
predominantly lower-lung reticular ground-glass opacities with irregular lines, traction bronchiectasis,
consolidation and lower lobe volume loss that is usually diffuse or subpleural in the axial dimension but
which sometimes spares the subpleural lung [32–34]. Honeycombing is generally absent. iNSIP is
distinguished radiographically from IPF by its spatial and temporal homogeneity, and (in some cases) by
the fact that it is subpleural sparing. The histology of iNSIP involves uniform alveolar and interstitial
mononuclear cell inflammation with preserved lung architecture that is almost always accompanied by
fibrosis [33].
Patients with fibrosing iNSIP have a restrictive ventilatory defect on lung function tests and a low DLCO
[32, 33]. The clinical presentation of iNSIP is nonspecific, with dyspnoea, cough and constitutional
symptoms frequently reported [33]. Progression is highly heterogeneous: some cases can remain stable or
improve, but others can progress to end-stage fibrosis [16, 17, 30]. A disease-behaviour classification is
therefore useful to manage patients with iNSIP [35]. Serial HRCT images from a patient with NSIP are
shown in figure 3.
Neovascularisation within intra-alveolar fibrotic lesions can be more extensive in lung tissues from patients
with fibrotic NSIP than patients with UIP [36]. The survival of patients with iNSIP may be poorer than
patients with NSIP associated with CTDs [37]. Furthermore, histopathological findings of organising
diffuse alveolar damage overlap or UIP overlap, or a clinical diagnosis of chronic HP overlap have been
associated with increased risk of death [38]. However, survival rates in iNSIP are usually higher than in
IPF [25, 39]. The 5-year survival rate has been reported to be 82% in iNSIP, whereas in IPF the median
survival is <5 years [5, 32]. The outcome of iNSIP can be influenced by immunosuppressive therapy [40],
and survival appears to be related to both lung function and histology [25, 41].
Unclassifiable IIP
IIPs may remain unclassifiable due to inadequate, nonspecific or conflicting clinical, radiological or
histopathological findings, or because patients are unwilling or unable to undergo lung biopsy [16, 17, 42,
43]. Unclassifiable IIP was first defined in international guidelines in 2013, meaning the disease has been
largely unrecognised and further investigation is needed for improved understanding [16, 44]. It has been
reported that ∼10% of all IIPs are unclassifiable [17, 30]. The risk factors for the prognosis of
unclassifiable IIP are not clearly defined.
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Some patients with unclassifiable IIP have one or more of the defined pathological entities (UIP or NSIP)
that characterise ILDs that may present a progressive-fibrosing phenotype [17, 44, 45]. Therefore,
unclassifiable IIPs often have a progressive fibrotic component and can present similarly to define ILDs
that may present a progressive fibrosing phenotype. Clinical features include dyspnoea, dry cough and
auscultatory crackles with no evidence of exposures or features of autoimmune disease [46]. HRCT
findings vary markedly, with mixed patterns of lung injury common. The prognosis for unclassifiable IIPs
may be slightly better than that of IPF, but the mortality rate is still high (estimated in one study to be
31% at 5 years) [17]. A low DLCO, the presence of a UIP-like fibrotic pattern on HRCT and the extent of
fibrosis on HRCT predict mortality in unclassifiable ILD [1, 17]. Patients with unclassifiable IIP and
HRCT features suggesting fibrosis (a high fibrosis score, the presence of honeycombing or the presence of
UIP or a possible UIP pattern) may have a poor prognosis, similar to patients with IPF [17]. The extent of
fibrosis, which can be measured by quantitative CT analysis, may help to predict outcomes in patients
with unclassifiable IIP [19].
CTD-ILD
CTDs, also known as collagen vascular diseases, encompass a spectrum of systemic immune diseases in
which self-reactive T- and B-cells produce circulating autoantibodies leading to inflammation and organ
damage [47, 48]. While the causes of these diseases are unknown, both genetic and environmental factors
appear to contribute [47, 49]. ILDs occur in ∼15% of all patients with CTDs, with higher rates in certain
conditions such as systemic sclerosis (SSc) and rheumatoid arthritis (RA), and they are associated with
varying rates of mortality [50, 51]. CTD-ILDs are the second most common diagnosis in tertiary ILD
referral centres [52, 53]. The risk of CTD-ILDs appears to be higher in women and in patients <50 years
of age [48].
CTD-ILDs can present with fibrosing lung injury, and HRCT assessments have shown that NSIP is the
most common pattern [48]. CTD-ILD may alternatively present with a pattern of UIP, and in this case it
is important to differentiate the disease from IPF. Expertise is needed to understand the radiological or
pathological features that enable differential diagnosis, and the frequent presence of comorbidities may
complicate the process [54, 55].
CTDs associated with fibrosing ILD include RA, SSc, idiopathic inflammatory myopathy (polymyositis
and dermatomyositis), Sjögren’s syndrome, systemic lupus erythematosus and mixed CTDs [48]. Of these
conditions, SSc and RA are most commonly associated with ILD, and these are discussed in more
detail below.
a) b) c)
FIGURE 3 Nonspecific interstitial pneumonia: high-resolution computed tomography images from a
46-year-old male patient who underwent lung transplantation. a) The initial scan, taken at first admission,
shows ground-glass attenuation and consolidation with reticulation and traction bronchiectasis along with a
bronchovascular bundle, sparing the subpleural lung. b) A follow-up scan 3 years later showed increased
ground-glass opacity and consolidation despite corticosteroids and immunosuppressive therapy. c) After
another 3 years, a decrease in ground-glass opacity and consolidation was evident, together with increased
traction bronchiectasis and cysts.
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RA-ILD
RA is characterised by swelling, tenderness and destruction of synovial joints, along with extra-articular
manifestations that can include pulmonary involvement [56, 57]. The mean age at diagnosis of RA is
∼60 years [58]. Under the age of 75 years, incidence rates of RA are up to four times higher in women
than men. Fibrosing ILD, the most common pulmonary manifestation of disease (occurring in ∼10% of
patients), is a major cause of morbidity and mortality in patients with RA and in some cases can be the
first symptom of RA [49, 59–61]. RA-ILD is believed to be caused by chronic immune activation and
inflammation, which stimulates fibroproliferation in the lung parenchyma of genetically susceptible
individuals. There are strong associations between RA-ILD and older age, male sex, cigarette smoking,
high rheumatoid factor titres and increased anti-citrullinated protein antibody levels [62].
When diagnosing RA-ILD, it is important first to rule out infection and drug-induced lung injury caused
by common RA medications, such as disease-modifying anti-rheumatic drugs and tumour necrosis
factor-ɑ inhibitors, which are known to cause pulmonary toxicity [49]. The histological lung injury in
RA-ILD can be any of the interstitial pneumonia patterns, including overlaps. Most studies report UIP and
NSIP as being the most common patterns, and coexisting UIP and NSIP are common in RA-ILD [63]. In
addition, lymphoid hyperplasia with germinal centres, and pleural and peribronchiolar lesions are more
common in RA-ILD than in IIPs, while fibroblastic foci are observed less frequently [64].
RA-ILD typically progresses faster in patients with UIP than other subtypes, although mortality rates are
variable [49]. Most RA-ILD patients with UIP have a similar slightly improved prognosis compared with
IPF, with acute exacerbations having a major impact on survival [57, 65–68]. Conversely, recently
published data suggest the existence of a subset of RA-ILD patients with UIP in whom the disease
stabilises in the long term, differentiating these patients from those with IPF [69].
SSc-associated ILD
SSc, also known as scleroderma, is an autoreactive immune CTD characterised by inflammation, immune
dysregulation, microvascular damage and progressive fibrosis of the skin and internal organs [70, 71]. The
peak onset of SSc is 30–70 years of age, with women being four times more likely to develop the disease
than men [72]. Fibrosing ILD is a very common manifestation of SSc and accounts for about one-third of
all disease-related deaths [73]. The pathogenesis of fibrosing SSc-associated ILD (SSc-ILD) is not clearly
understood but is believed to involve repetitive epithelial injury, activation of innate and adaptive immune
mechanisms, and fibroblast recruitment and activation leading to extracellular matrix accumulation and
fibrosis [74]. SSc is characterised by small vessel vasculopathy, autoantibody production and fibroblast
dysfunction subsequently leading to extracellular matrix deposition [75].
Key features of SSc-ILD include pulmonary fibrosis, most pronounced in the basilar portions of the lungs,
and “velcro” crackles on auscultation that cannot be attributed to another cause [71, 74]. Most patients
have a fibrotic NSIP pattern on HRCT, with a high proportion of ground-glass opacities (peripheral
distribution with subpleural and basilar predominance) and a low proportion of course reticulation
[74, 76, 77]. However, a UIP pattern may sometimes be seen [74, 77].
Symptoms of SSc-ILD include exertional dyspnoea, non-productive cough and fatigue [74, 77]. Lung
function tests generally show a restrictive ventilatory deficit with a low DLCO. Nearly all SSc-ILD patients
test positive for antinuclear antibodies, and SSc-specific antibodies (e.g. anti-topoisomerase I) are
commonly found [74]. Median survival among patients with SSc-ILD appears to be better than among
IPF patients, probably because of the higher prevalence of the NSIP pattern [77–79]. The extent of disease
on HRCT has been shown to be an independent predictor of mortality [80].
HP
HP (also known as extrinsic alveolar alveolitis) is a complex, diffuse ILD caused by repeated exposure and
sensitisation to an inhaled antigen, most commonly avian, microbial (especially moulds) or chemical
[81, 82]. HP is the third most prevalent ILD diagnosis after IPF- and CTD-ILDs [53]. It is believed that
antigen inhalation results in type III/IV hypersensitivity reactions, which cause alveolar epithelial injury
[83]. Abnormal repair mechanisms may then lead to fibroblast expansion/activation, excessive collagen
deposition (through accumulation of the extracellular matrix) and destruction of the lung architecture,
similar to that seen in IPF [83, 84]. The principal forms of HP are acute/subacute and chronic [82, 85].
Acute/subacute HP is predominantly characterised by influenza-like symptoms (e.g. fever, cough and
dyspnoea) that emerge 2–9 h after exposure to an antigen, and may last or increase over a period of hours or
days [82]. Patients with chronic HP have slowly progressive disease, with dyspnoea, cough, fatigue and weight
loss [81, 82]. The chronic form of HP arises from repetitive, low-level exposure to the causative antigen,
but the identity of the causative antigen may remain unknown in more than half of all cases [82, 86].
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The search for a cause of chronic HP may include consideration of specific circulating immunoglobulin G
antibodies [16].
Fibrosis develops in many patients with chronic HP. Because of its similarity to IPF, chronic fibrotic HP is
difficult to diagnose [87–92]. On HRCT, a “possible UIP” pattern of fibrosis is often seen in fibrosing HP
[93]. Potential radiological features that distinguish chronic HP from UIP include: a patchy pattern of
ground-glass opacities with upper lung predominance; a combination of ground-glass, reticular and
centrilobular nodular opacities with fibrosis; and lobular areas with mosaic attenuation and air trapping
[16, 81, 84, 90, 91]. The diagnosis can be supported by lymphocyte predominance on bronchoalveolar
lavage, although the absence of this finding should not exclude the diagnosis of fibrosing HP [84].
Potential histological findings include fibrosis in a bronchiolocentric pattern, infrequent or inconsistently
distributed fibroblast foci, a variable number of poorly formed granulomas, giant cells, inflammation,
organising pneumonia or chronic bronchiolitis [16, 94]. An international group of experts recently
attached highest importance to the following diagnostic criteria for chronic HP: identification of a
causative antigen, time relation between exposure and disease, mosaic attenuation on chest imaging, and
poorly formed non-necrotising granulomas on pathology [95].
The natural history of fibrosing HP with a UIP pattern is similar to IPF, whereby progression occurs
despite treatment with an agent considered appropriate for the ILD. However, in other subsets of patients
with HP, fibrosis that initially appears progressive may stabilise in the longer term in response to therapy.
Chronic fibrosing HP develops over a period of months to years, and is usually consequential to
continuous low-level exposure to the causal antigen, although in a significant number of cases an
aetiological agent cannot be found. Patients with chronic HP have significantly worse health-related
quality of life than those with IPF [96]. The median survival from diagnosis of chronic HP is ∼5 years [86].
HP with either a UIP-like or an NSIP pattern may be associated with similar survival rates to IPF [81].
Potentially fatal acute exacerbations of HP have been reported [97]. The extent of fibrosis on HRCT in
patients with chronic HP is predictive of mortality [86, 92, 98–101].
Sarcoidosis
Sarcoidosis is a rare systemic, inflammatory disease of unknown aetiology [102]. It may result from a
chronic immunological response to an unknown antigen(s) in genetically susceptible individuals.
Approximately 90% of patients with sarcoidosis have pulmonary involvement [103]. Signs and symptoms
of pulmonary sarcoidosis include dry cough, chronic dyspnoea on exertion, chest tightness, wheezing,
hypoxaemia and lung function decline [102, 104].
Approximately 20% of patients with pulmonary sarcoidosis develop pulmonary fibrosis (stage IV
sarcoidosis), which is associated with significant morbidity and mortality [102]. Pulmonary fibrosis
predominantly affects the upper lobes (posterior segments) and is airway-centred with no air trapping; the
fibrosis tends to follow the bronchovascular bundles [105]. The extent and type of fibrosis are highly
variable. Imaging tends to reveal faint reticulations to dense linear bands, cystic lung disease, traction
bronchiectasis and airway distortion [104]. Extensive parenchymal destruction and mycetoma are also
occasionally observed. A UIP pattern of lung injury is uncommonly seen in patients with fibrosing
pulmonary sarcoidosis, although honeycombing may be seen in the upper zones of the lungs [105].
The natural history of lung function decline in patients with sarcoidosis has not been well established
[102]. A 10-year mortality rate of 16% has been reported in patients with lung fibrosis [106], which,
allowing for comorbidities and other causes of death, may suggest that a small subset of patients have the
progressive-fibrosing phenotype despite appropriate therapy. Acute exacerbations have not been reported
in stage IV pulmonary sarcoidosis [105].
ILDs related to other occupational exposures
ILDs related to other occupational exposures are caused by inhalation and retention in the lungs of
various dusts. The most common of these conditions are: asbestosis, which is caused by asbestos fibres;
and silicosis, which is related to free crystalline silicon dioxide or silica [107–109]. Exposure to farming,
livestock, metal dust, coal, sand and dust arising from the preparation of dental prosthetics have also been
linked to the development of ILDs [110]. ILDs related to other occupational exposures are diagnosed
principally from exposure history and imaging. In simple silicosis, multiple, small rounded nodules of
hyalanised collagen are visualised using HRCT as bilateral nodules in the upper lobes [110]. In more
advanced, complicated silicosis, convergence of the nodules may result in larger opacities, which can
develop into a progressive massive fibrosis pattern in the upper lobes, comparable to pulmonary fibrosis in
sarcoidosis. However, some patients with silicosis present with a UIP pattern [111, 112]. In fibrosing
asbestosis, HRCT findings resemble those seen in IPF [108]; some patients may have pleural thickening
and/or plaques, which are suggestive of asbestos exposure. Additionally, histology may reveal iron-coated
https://doi.org/10.1183/16000617.0076-2018 7
PROGRESSIVE-FIBROSING ILD | V. COTTIN ET AL.
asbestos fibres (“asbestos bodies”) embedded in the peribronchiolar interstitium and alveolar spaces, which
are the hallmark of asbestosis [113].
Progression of silicosis from simple to complicated disease is generally slow and can take >10 years [109].
For fibrosing asbestosis, the prognosis is usually better than for IPF because mild disease progresses slowly,
although deterioration is quicker in patients retaining larger quantities of asbestos in the lungs [114].
According to a US study of individuals dying from asbestosis, the condition shortens life by a median of
8 years [115]. As there are no known treatments for ILDs related to other occupational exposures,
avoidance of exposure is the only means of reducing the burden of disease.
Conclusion
Progressive fibrosis is an important characteristic of several ILDs that is strongly linked with morbidity
and mortality. Although individual ILDs that may present a progressive-fibrosing phenotype have
distinguishing features in terms of their clinical, radiological and histopathological presentations, they also
have many overlapping characteristics that are similar to the classical fibrosing ILD with a progressive
phenotype, IPF. Antifibrotic therapy is currently being investigated in these diseases. Accurate and early
diagnosis is challenging but crucial to ensure that each patient receives treatment that is appropriate for
the rate of progression seen with their particular disease.
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